21st August 2018: A new chapter in the provision of advanced cancer care in the North-East of England has started with the official opening of the Rutherford Cancer Centre North East.
8th August 2018: The provision of advanced cancer treatment in the South of England passed a key milestone today with the arrival of the first high energy proton beam therapy system in the region.
7th August 2018: The first patient to be treated with high energy proton beam therapy for breast cancer in the UK commenced treatment this week at the Rutherford Cancer Centre South Wales.
11th April 2018: Proton Partners International announced today it has treated the first patient in the UK with high energy proton beam therapy.
20th March 2018: Proton Partners International has been granted formal technical and regulatory approval from Healthcare Inspectorate Wales to begin treating patients with proton beam therapy at its Rutherford Cancer Centre in Wales.
12th March 2018: IBA, the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed three new contracts with Proton Partners International, to install three Proteus®ONE* compact proton therapy solutions across the UK.
7th March 2018: Wales has shown ‘outstanding’ vision in helping to develop innovative proton beam therapy services for cancer patients.
22nd February 2018: Proton Partners International and Ion Beam Applications (IBA) Group, the world’s leading developers of high energy proton beam therapy centres and systems, have officially completed testing on the UK’s first high energy proton beam machine, the Proteus®ONE.
6th February 2018: The first proton beam therapy system to be installed in the North-East of England was delivered today by Proton Partners International Ltd.
Two members of Proton Partners International staff have been ranked amongst the ‘high performers’ in an international proton planning study carried out by the Particle Therapy Co-Operative Group (PTCOG) and the Mayo Clinic.
Jamil Lambert, a physicist, and Karen O’Neill, a dosimetrist, took part in the international, multi-institutional quality improvement project in which the PTCOG paediatric group invited experts to submit a treatment plan using proton beam therapy on a paediatric patient.
The goal of the study was to learn the best proton beam therapy techniques and share the findings with the wider community. The patient’s CT and all of the structures were provided, and then the individual centres used their own beam models and treatment techniques to create a treatment plan.
Plans were assessed depending on whether it met the treatment goals. High scoring plans, like those submitted by Jamil and Karen, are those which had a good dose coverage of the target, as well as delivering a low dose to all of the organs at risk.
The results were first presented at the 2017 International PTCOG meeting in May 2017 in Japan.
Mike Moran, chief executive officer of Proton Partners International, said: “We have recruited some of the leading cancer specialists in the country and it’s great to see that their talents have been recognised in this study.
“Two important words for us are ‘innovation’ and ‘collaboration’ – both of which are central to our company ethos. By participating in this global study, Jamil and Karen have demonstrated that they are playing their part in the wider research effort, and sharing data is a key part of that. They have also shown that it’s essential we work collaboratively to innovate, in proton beam therapy and in other areas, so that we can learn from each other and build a greater level of expertise together.”
The results of the study can be accessed here.